IDEXX Raises 2026 Outlook After 10% Revenue Growth and 18% EPS Gain
IDEXX Laboratories raised its 2026 revenue and earnings outlook after third-quarter sales rose 10% on strong demand for its veterinary diagnostics.
Revenue reached $1,214 million, up 10% on both a reported and organic basis, and earnings rose 18% to $4.01 per diluted share, the pet health company said in an 8-K Monday. On a comparable basis, EPS grew 22%.
Diagnostics drive growth
Companion Animal Group diagnostics recurring revenue grew 11%, including 10% growth in the U.S. and 13% reported growth in international regions, according to the release. IDEXX VetLab consumables revenue grew 14%.
The company placed more than 1,900 IDEXX inVue Dx analyzers during the quarter. CEO Mike Erickson pointed to new tools including inVue Dx and IDEXX Cancer Dx, and to the acquisition of CoVet, an AI clinical assistant for veterinary teams.
Third-quarter EPS included a 3-cent gain on an equity investment, a 1-cent tax benefit from share-based compensation and a 4-cent benefit from currency changes.
Raised outlook
IDEXX now expects 2026 revenue of $4,741 million to $4,767 million, up $32 million at the midpoint, and EPS of $14.96 to $15.16, a 25-cent increase from the prior midpoint. It expects reported revenue growth of 10.1% to 10.8% and organic growth of 9.3% to 10.0%.
By the numbers
- $1,214 million revenue, up 10%
- $4.01 EPS, up 18%
- 11% CAG Diagnostics recurring revenue growth
- $14.96 to $15.16 raised 2026 EPS outlook
Sources
- IDEXX Laboratories Form 8-K with third-quarter 2026 results, filed Nov. 2, 2026 (accession 0001104659-26-120892)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.